Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term CARCINOMA. Found 53 abstracts

no pagination
Gowrishankar B, Ibragimova I, Zhou Y, Slifker MJ, Devarajan K, Al-Saleem T, Uzzo RG, Cairns P. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biology & Therapy. 2014 Mar;15(3):329-41.   PMCID: PMC3974843
Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, Rubin SC, Boyd J, Gimotty PA, Coukos G. Intraepithelial T Cells and Tumor Proliferation. Cancer. 2009 Jul;115(13):2891-902.   PMCID: PMC2754811
Cooper JS, Porter K, Mallin K, Hoffman HT, Weber RS, Ang KK, Gay EG, Langer CJ. National cancer Database report on cancer of the head and neck: 10-year update. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 2009 Jun;31(6):748-58.
Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT. Risk stratification for desensitization of patients with carboplatin hypersensitivity: Clinical presentation and management. Journal of Allergy and Clinical Immunology. 2009 Jun;123(6):1262-7.
Howard JH, Frolov A, Tzeng CW, Stewart A, Midzak A, Majmundar A, Godwin AK, Heslin MJ, Bellacosa A, Arnoletti P. Epigenetic downregulation of the DNA repair gene MED1/MBD4 in colorectal and ovarian cancer. Cancer Biology & Therapy. 2009 Jan;8(1):94-100.   PMCID: PMC2683899
Kadariya Y, Yin B, Tang BQ, Shinton SA, Quinlivan EP, Hua X, Klein-Szanto A, Al-Saleem TI, Bassing CH, Hardy RR, Kruger WD. Mice Heterozygous for Germ-line Mutations in Methylthioadenosine Phosphorylase (MTAP) Die Prematurely of T-Cell Lymphoma. Cancer Research. 2009 Jul;69(14):5961-9.   PMCID: PMC2757012
Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Johnson FM, Green S, Gualberto A. Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 2009 May;27(15):2516-22.   PMCID: not NIH funded
Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases. Journal of Clinical Oncology. 2009 Apr;27(10):1572-8.   PMCID: not NIH funded
Tian CQ, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, Rose PG, Spriggs D, Armstrong DK, Gynecologic Oncology Grp Study; Gynecologic Oncology Grp S. CA-125 Change After Chemotherapy in Prediction of Treatment Outcome Among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers A Gynecologic Oncology Group Study. Cancer. 2009 Apr;115(7):1395-403.   PMCID: PMC 2743569
Berger AC, Garcia M, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB, MacDonald J, Willett CG. Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704. Journal of Clinical Oncology. 2008 Dec;26(36):5918-22.
Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. Journal of Clinical Oncology. 2008 Oct;26(29):4708-13.
Cohen SJ, Engstrom PF, Lewis NL, Langer CJ, McLaughlin S, Beard M, Weiner LM, Meropol NJ. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. American Journal of Clinical Oncology-Cancer Clinical Trials. 2008 Feb;31(1):1-5.
Cvetkovic D, Williams SJ. Are there precursor lesions for ovarian cancer: A review. Srpski Arhiv Za Celokupno Lekarstvo. 2008 Mar;136:48-53.
Darcy KM, Brady WE, McBroom JW, Bell JG, Young RC, McGuire WP, Linnolia RI, Hendricks D, Bonome T, Farley JH. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008 Dec;111(3):487-95.
Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02. European Urology. 2008 Oct;54(4):816-24.
Hajdu SI, Ehya H. A note from history: Foundation of diagnostic cytology. Annals of Clinical and Laboratory Science. 2008 Jan;38(3):296-9.
Huang QH, Gumireddy K, Schrier M, Le Sage C, Nagel R, Nair S, Egan DA, Li AP, Huang GH, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Pure E, Agami R. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nature Cell Biology. 2008 Feb;10(2):202-U83.
Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecologic Oncology. 2008 Aug;110(2):140-5.
McMeekin DS, Walker JL, Hartenbach EM, Bookman MA, Koh WJ. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008 Jan;112(1):134-41.
Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma - A randomized controlled trial. JAMA-Journal of the American Medical Association. 2008 Mar;299(9):1019-26.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term CARCINOMA

CARCINOMA PACLITAXEL SURVIVAL EXPRESSION CANCER RADIOTHERAPY CHEMOTHERAPY TRIAL STAGE-III THERAPY PROTEIN GYNECOLOGIC-ONCOLOGY-GROUP ovarian cancer ADENOCARCINOMA PHASE-III INHIBITION EXPERIENCE CELLS CURATIVE RESECTION DEFICIENCY TUMORS PROGNOSTIC-FACTORS cell RCC OVARIAN-CANCER methylation SENSITIZER ANGIOGENESIS KIDNEY CANCER BREAST-CANCER cetuximab HORMONE AGONISTS PATHWAYS IMMEDIATE EPIDERMAL-GROWTH-FACTOR progression CODELETION RESISTANCE CETUXIMAB ANAPHYLAXIS PLATINUM-BASED CHEMOTHERAPY GENE DELETION clear MEN ORNITHINE-DECARBOXYLASE GENE-MUTATIONS ANTIGENS GENE-REGULATION STEM-CELLS CARBOPLATIN DIFFERENTIATION HOMOZYGOUS DELETIONS papillomatosis TONSIL cancer EXFOLIATIVE CYTOLOGY PRIMARY CYTOREDUCTIVE SURGERY CHEMOTHERAPY-NAIVE PATIENTS LUNG FAMILY-HISTORY proteasome inhibitor IGF GROUP EXPERIENCE Prostate cancer MESSENGER-RNA CISPLATIN NEEDLE ASPIRATION BIOPSY GEMCITABINE inclusion cysts carboplatin FENRETINIDE MED1 Oncology IHC CD44S EXPRESSION PROTOCOL TISSUE Advanced endometrial cancer MUTATIONS COOPERATIVE-ONCOLOGY-GROUP Ovarian cancer radiation therapy Overexpression GROWTH RNA head and neck cancer Cisplatin history of cancer history of cytology-history of smear techniques-landmarks in cytology Whole abdominal FACTOR-KAPPA-B CELL LUNG-CANCER HUMAN-PAPILLOMAVIRUS CISPLATIN-BASED CHEMOTHERAPY INTRAPERITONEAL CISPLATIN PHASE-III TRIAL phase II PROGNOSTIC-SIGNIFICANCE BODY-COMPOSITION ALLERGY MED1 MBD4 SURFACE EPITHELIUM capecitabine CAPILLARIES OVER-EXPRESSION DOSE CHEMOTHERAPY colorectal cancer FEASIBILITY PHARMACODYNAMIC END-POINTS Prognostic markers oxaliplatin Paclitaxel MODEL SERUM CA-19-9 CDKN2 clear cell cancer CA-125-mucinous cell cancer-ovarian cancer ISLAND METHYLATOR PHENOTYPE Hormonal therapy SBRT p53 T cells ovarian cancer-surgical cytoreduction-tumor proliferation GENE PHENOTYPE GLYCOSYLASE MBD4 HMLH1 STATISTICS PRETREATMENT CA-125 INFILTRATING LYMPHOCYTES SUPPRESSION PLASMA-LEVELS precancer national cancer database REPLACEMENT Radiation therapy nationwide RADIATION-THERAPY drug allergy Desensitization-carboplatin-ovarian cancer-skin testing-hypersensitivity C-MYC PROMOTER HYPERMETHYLATION COLORECTAL-CANCER UNITED-STATES BONE-MINERAL DENSITY IDENTIFICATION paclitaxel TRENDS ABDOMINOPELVIC IRRADIATION expression MONOCLONAL-ANTIBODIES GROWTH-FACTOR VEGF MUTATION PROPHYLACTIC OOPHORECTOMY SPECIMENS INSTABILITY
Last updated on Friday, January 03, 2020